Last reviewed · How we verify

Afluria Influenza Vaccine

Seqirus · Phase 2 active Biologic

Afluria Influenza Vaccine stimulates the body's immune system to produce antibodies against the influenza virus.

Afluria Influenza Vaccine stimulates the body's immune system to produce antibodies against the influenza virus. Used for Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older..

At a glance

Generic nameAfluria Influenza Vaccine
Also known asAfluria
SponsorSeqirus
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 2

Mechanism of action

This vaccine works by introducing a small, harmless piece of the influenza virus to the body, which triggers an immune response and helps the body recognize and fight the virus in the future.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: